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Recognition and stigma of prescription
drug abuse disorder: personal and
community determinants
Robert Shupp1* , Scott Loveridge2, Mark Skidmore3, Brandn Green4 and Don Albrecht5
Abstract
Background: Prescription drug abuse (PDA) disorders continue to contribute to the current American opioid crisis.
Within this context, our study seeks to improve understanding about stigma associated with, and symptom
recognition of, prescription drug abuse.
Aims: Model the stigma and symptom recognition of PDA in the general population.
Methods: A randomized, nation-wide, online, vignette-focused survey of the general public (N = 631) was
implemented with an oversample for rural counties. Logit estimation was used for analysis, with regional and
county-level sociodemographic variables as controls.
Results: Individual respondents that self-identify as having or having had “a prescription drug abuse issue” were
less likely to correctly identify the condition and were 4 times more likely to exhibit stigma. Male respondents were
approximately half as likely to correctly identify PDA as female respondents while older respondents (55+) were
more likely to correctly identify PDA, relative to those aged 35–54. Being both male and younger was associated
with slightly more stigma, in that they were less likely to disagree with the stigma statement.
Conclusions: In light of the continued risks that individuals with PDA behaviors face in potentially transitioning to
illicit opioid use, the findings of this survey suggested a continued need for public education and outreach. Of
particular note is the perspective of those who have self-identified with the condition, as this population faces the
largest risks of adverse health outcomes from illicit drug use within the survey respondents.
Keywords: Prescription drug, Opioid, Stigma, Recognition, Survey
Background
Prescription drug misuse is a critical public health issue
in the United States. In 2015, prescription drug misuse
accounted for 52,404 deaths, 63.1% of which involved
opioids [1]. Addressing the opioid crisis is a current na-
tional priority, with leading federal agencies and the Of-
fice of the President providing extensive funding and
support for increasing treatment access and the use of
evidence-based practices. Within the context of this
rapid expansion of treatment services, questions remain
about the general level of knowledge about PDA and the
potential influence stigma about PDA has on the pursuit
of treatment or participation in prevention programming
efforts [2, 3]. In what follows we rely on the Mayo Clinic
definition of PDA [4], the Mental Health First Aid defi-
nitions of recognition and Griffiths, Christensen, and
Jorm [5] for stigma.
The sequence from misuse of prescription drugs to
illicit drug use has been identified as a key pathway to
addiction that has contributed to the opioid overdose
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crisis [6]. Raising public knowledge and reducing stigma
about PDA can also improve health outcomes and re-
duce substance misuse [7]. In this paper, the stigma as-
sociated with PDA and the recognition of PDA among
family and friends are examined to elucidate how
individual-level interventions aimed at stigma reduction
and PDA recognition may also contribute to turning
back the tide of opioid overdoses.
Recognition of PDA in the early stages of its development
may help the individual begin to take appropriate remedies
before the condition is fully developed [8]. Furthermore,
recognizing the condition as a disease to be treated rather
than simply a problem of personal character could help in-
dividuals seek treatment more quickly [9]. Since the inci-
dence of PDA varies by place, an important strategy for
addressing the challenge of PDA is to explore the not only
individual, but also community-level factors associated with
recognition and stigmatization. In short, a better under-
standing of the personal and community characteristics as-
sociated with PDA recognition and stigma can assist in
design of programs to combat the opioid crisis.
To study the statistical relationships of recognition
and stigma in the context of PDA, we used a survey ap-
proach. Specifically, we implemented a national survey
to identify respondent and community characteristics that
increase the probability of recognizing and stigmatizing
the condition of PDA. Over 30% of respondents could not
correctly identify the condition associated with the vi-
gnette that described an individual with symptoms/behav-
iors commonly associated with PDA. With respect to
PDA stigma, correct identification of the condition is
strongly associated with less agreement with a stigmatiz-
ing statement about the condition. In addition, respondent
characteristics such as age and education are predictors of
both recognition and stigma as are several county-level
variables. The results help inform how to target PDA pre-
vention efforts. Results also imply that mental health pro-
viders might be an important ally in future efforts to
improve recognition rates and address stigma.
Methods
The prescription drug abuse survey took place in July,
2016. The IRB was approved by Michigan State University
Human Research Protection Program on October 1, 2014.
Survey Sample International (SSI) was used to obtain a na-
tionally representative respondent pool as well as a rural
over-draw. The SSI company maintains a large opt-in
panel of survey respondents balanced on age, gender, in-
come and region. Opt-in panels are increasingly accepted
in survey work as response rates from phone and mail sur-
veys are dwindling. Opt-in panels seem to produce results
comparable to robust traditional surveys, but at lower ex-
pense [10]. We requested additional respondents from
rural areas to investigate the role that rural areas may play
in recognition and stigma as, seemingly, in contrast to
prior outbreaks of drug abuse epidemics, there is anec-
dotal evidence of PDA higher incidence in rural areas.
Additional rural respondents were drawn from randomly
selected rural counties as defined by the 2013 USDA Rural
Urban Continuum Codes (counties with a code of 7, 8
and 9) and was also balanced on age, gender and income
to the extent possible. A national pretest was used to help
finalize the survey design.
The survey was opened to the SSI panel until the re-
quired number of responses was obtained from each cat-
egory (gender, income, region, etc.) required for a
balanced response set; thus there is no response rate as
classically defined in survey research. The survey instru-
ment presented respondents with a vignette that de-
scribed an individual with symptoms/behaviors
commonly associated with PDA. To account for possible
gender effects half the respondents (approximately 250
national draw and 63 rural draw) received a vignette
about a woman (Michelle) while the other half received
a vignette about a man (Michael). Generally, the vignette
is based on those found in Jorm et al. [11]. The Michael
version of the vignette used in the survey follows.
Vignette: Michael is 30 years old. He went to see his
doctor after experiencing a work-related injury and the
doctor prescribed a painkiller, hydrocodone (brand
names: Vicodin, Norco, Lortab), for Michael to take. He
started taking the painkiller as instructed by the doctor
but felt like it was not enough to control his pain and
started taking an extra pill every day. After a follow-up
visit, the doctor told Michael that his injury had healed
and that he should stop taking the painkiller, but he
continued taking it until he ran out. At that point, he felt
like he needed more of the painkiller and went to a new
doctor to get a new prescription.
A total of 631 respondents completed the survey. After
reading the vignette, the respondent was asked a series of
questions about what might be wrong with the person de-
scribed in the vignette, how that person might be helped,
and a series of questions designed to measure the respon-
dent’s stigma regarding people like the one in the vignette.
We adapted stigma questions from Griffiths, Christensen,
and Jorm [5] to reflect the appropriate issue and to better
fit our US context, as their work originated in Australia.
Given that it is likely that personal experience in dealing
with prescription drug use disorders, either in oneself or a
family member, will impact recognition and/or stigma re-
sponses, subsequent to the vignette and recognition,
stigma, and help-seeking questions, respondents were asked
about their own and family member/close friend history of
PDA. In addition, standard sociodemographic questions
were included to be used to further explore the determi-
nants of recognition and stigma. All results, except the rec-
ognition and stigma response proportions, are presented in
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unweighted format due to our use of socio-economic con-
trols used by SSI to recruit a balanced sample. While we
constructed weights for the response proportions, using
weights in a regression that also uses the variables used to
construct the weights would introduce bias.
In the following analysis, the primary data from the sur-
vey is matched with regional level indicator variables as well
as a selection of county-level secondary data drawn from
the Robert Wood Johnson Foundation-funded County
Health Rankings project at the University of Wisconsin.
While the University of Wisconsin data provides counts of
mental health services providers, there are many missing
values so mental health coverage quartiles, which are more
complete, are used instead of counts. Finally, consistent
with observations by Cerdá et al. [12] we proxy state-level
community health norms with each state’s position with re-
spect to loosening of restrictions on marijuana. We draw
the state’s legalization position from an inventory produced
by Governing magazine [13].
Analysis of recognition uses multilevel mixed-effects
logit estimation with respondent, regional and county-
level sociodemographic variables as controls. Analysis of
the responses to stigma questions is conducted using a
generalized linear multilevel multinomial logit estima-
tion procedure, again using controls. We selected multi-
nomial logit for analysis of the stigma data because it
allows the response categories to be unordered, and our
Table 1 Summary statistics for prescription drug abuse regression variables
Variables Min. Max. Mean Std. Dev. 2017 American Community Survey Estimatesa
Own Prescription Drug Abuse: Yes 0 1 0.138 0.345 –
Family/Friend Prescription Drug Abuse 0 1 0.338 0.473 –
Male 0 1 0.425 0.495 0.487
White 0 1 0.849 0.358 0.730b
ID: Prescription Drug Abuse 0 1 0.678 0.468 –
Age 18–34 0 1 0.323 0.468 0.243c
Age 55+ 0 1 0.319 0.466 0.276
Income <$25 K 0 1 0.200 0.400 0.214
Income $25-50 K 0 1 0.247 0.432 0.225
Income $75-100 K 0 1 0.171 0.377 0.123
Income $100 K+ 0 1 0.190 0.393 0.262
Education: some college 0 1 0.307 0.462 0.208
Education: college degree 0 1 0.273 0.446 0.274d
Education: college above bachelors 0 1 0.166 0.373 0.118
Name: Michelle 0 1 0.502 0.500 –
Northeast 0 1 0.176 0.381 0.172
Midwest 0 1 0.244 0.430 0.210
West 0 1 0.225 0.418 0.238
aSource: American Fact Finder. American Community Survey (ACS) 2017
bWhite race alone. Proportion white race and other races in ACS is 0.757
cCensus reports 15–19 age bracket. Two-fifths of that age bracket were added to the 20 to 34 age brackets to estimate the ACS 18–34 proportion
dCombined bachelors and associates degrees
Table 2 Summary Statistics for Prescription Drug Abuse
Regression Variables (County-Level Public Data)
Variables Min. Max. Mean Std. Dev.
Rural 0 1 0.201 0.401
Unemployment 1 17 8.394 2.571
Association Rate 0.165 4.741 1.091 0.543
Percent fair or poor health 7 36 16.312 4.486
Percent access to exercise 0 100 79.198 22.972
Percent uninsured 3 35 16.824 5.739
Percent frequent physical distress 7 20 11.333 2.149
Percent frequent mental distress 7 17 11.179 1.683
Percent lack of sleep 23 45 33.876 3.660
Percent physically inactive 9 41 23.762 5.755
2nd Quartile 0 1 0.263 0.441
3rd Quartile 0 1 0.171 0.377
4th Quartile 0 1 0.119 0.324
Percent excessive drinking 9 26 17.643 2.969
Percent alcohol driving deaths 0 100 30.450 11.033
Violent crime rate 0 1190 368.210 230.012
Percent child poverty 4 51 22.631 8.228
Legalized Marijuana State Law 0 1 0.661 0.474
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survey allowed the “don’t know” option in the Likert-
type questions, and a priori “Don’t know” is neither
higher nor lower than, say, “strongly agree.” The neutral
“neither agree nor disagree” category was used as the
base response for the stigma analysis. The strongly (dis)
agree and (dis) agree categories were combined in the
multinomial logit analysis to facilitate interpretation. In
the multinomial logit model the log-odds of each re-
sponse is expressed as follows: μij ¼ log πijπiJ ¼ α j þ x
0
iβ j,
where αj is a constant and βj is a vector of regression
coefficients, for j = 1, 2,..., J-1. This model is similar to
the binary outcomes model except that it extends to
more than two outcomes. See Aldrich and Nelson [14]
for a discussion of the procedure.
Results
Tables 1 and 2 provides the summary statistics for respond-
ent, regional and county-level sociodemographic variables.
To provide a comparison with national statistics, American
Community Survey data are provided in the last column of
Table 1, which covers the individual-level data provided by
respondents. Note that the self-reporting of prior experi-
ence with prescription drug abuse by the respondent
(13.8%) is slightly lower, but comparable to other measures.
For example, a 2015 national survey by the Substance
Abuse and Mental Health Services Administration
(SAMHSA) suggests around 20% of those aged 12 or older
have misused or abused prescription drugs at least once in
their life [15]. Table 2 provides survey-level frequencies of
public county or state level data matched to respondents.
To prevent respondents from not selecting the correct
recognition response because they were trying to decide be-
tween two or more options, the survey question used to
measure recognition allowed multiple responses (i.e., select
all that apply). Despite this, while the majority of respon-
dents selected the correct condition (PDA), a large propor-
tion (32% - see Table 3) did not correctly identify the
problem. The three next most selected responses were ‘has
a problem’ (29%), ‘depression’ (13%), and ‘stress’ (10%).
While ‘has a problem’ is generic enough to be true for
many issues, depression and stress are often considered
precursors and/or symptoms of PDA [16, 17]. Four percent
of respondents thought there was nothing wrong with the
person in the vignette. Figure 1 reports the percentages for
each response category for the question measuring stigma
– “X’s problem is not a real medical illness”. Twenty
Table 3 What is wrong with X? Multiple response question
(percentages)
Survey Response Option Proportion
Depression 0.13
Nervous Breakdown 0.04
Schizophrenia/Paranoid Schizophrenia 0.01
Mental Illness 0.05
Psychological/Emotional Problems 0.09
Stress 0.10
Has a Problem 0.29
Cancer 0.02
Nothing 0.04
Other 0.02
Don’t Know 0.06
Alcohol Abuse 0.03
Prescription Drug Abuse 0.68
Physical Injury 0.09
Anxiety Disorder 0.07
Number of respondents 631
Fig. 1 Stigma – X’s problem is not a real medical illness – Frequencies (percentages)
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percent of respondents indicated high levels of stigma (se-
lected “strongly agree” or “agree”), while 58% of respon-
dents indicated low levels or no stigma (selected “strongly
disagree” or “disagree”) and 16% indicated middling levels
of stigma.
Recognition regression results
Table 4 presents the results of the recognition multi-level
mixed-effects logit estimations. The farthest right column
(Exp(B)) shows the influence of the associated variable on
probability of selecting the correct condition (“Prescription
Drug Abuse”), with values greater than (less than) one indi-
cating an increased (decreased) probability. With regard to
respondent level variables, respondents that self-identify as
having or having had “a prescription drug abuse issue” are
less likely to correctly identify the condition. Gender, age
and education also play a significant role in PDA recogni-
tion. Male respondents are approximately half as likely to
correctly identify PDA as female respondents while older
(55+) respondents were more likely to correctly identify the
condition, relative to those aged 35–54. Relative to the base
level of education (high school or less), a higher level of
education consistently leads to a higher likelihood of cor-
rectly identifying PDA. However, it is only significant in the
“some college” and “college degree” categories (twice as
likely). Finally, the gender of the person described in the vi-
gnette (Michael or Michelle) did not appear to play a role
in respondent recognition of PDA.
In terms of the regional and county-level variables, the
only statistically meaningfully significant factor with re-
gard to PDA recognition was if the respondent was from
a county in the highest quartile of mental health pro-
viders per capita.1 Relative to those from counties in the
lowest quartile respondents in the highest quartile coun-
ties were less than half as likely to correctly identify the
condition as PDA.
Stigma regression results
For the stigma question, we report the results of a gener-
alized linear multilevel multinomial logit estimation pro-
cedure with “neither agree nor disagree” as the base
category. Table 5 presents results for “strongly agree/
agree” and “strongly disagree/disagree”, while the “don’t
know” category results are presented in Table 6 and
show that the differences between “don’t know” and
“neither agree nor disagree” responses are significant
enough to suggest that combining the two categories for
the analysis is inappropriate.2
1Meaningful in this context meaning the Exp(B) is more than slightly
different than one.
2Note that for the “don’t know” regression in Table 6 we report simple
multinomial logit estimations (with regional controls) instead of a
multilevel analysis since the multilevel version would not converge.
Table 4 Multilevel mixed-effects logit estimation: prescription
drug abuse recognition
Sig. Exp (B)
Respondent Variables:
Own Prescription Drug Abuse 0.000 0.345
Friend/family Prescription Drug Abuse 0.169 1.411
Male 0.006 0.541
White 0.085 1.582
[Age base = 35–54]
Age 18–34 0.060 0.649
Age 55+ 0.000 2.909
[Respondent Income: base = $50–75)]
$25 K or less 0.466 1.299
$25-50 K 0.492 1.250
$75-100 K 0.976 1.010
$100 K+ 0.561 1.206
[Respondent Education: base = HS or less]
Some college 0.018 2.019
College degree 0.024 2.034
More than College 0.787 1.099
[Sufferer in Vignette: base = Michael]
Michelle 0.302 1.236
Regional Level Variables:
Northeast 0.279 0.644
Midwest 0.637 1.190
West 0.655 1.251
County Level Variables:
Rural 0.390 1.408
Unemployment 0.833 0.986
Association Rate 0.415 0.789
Percent fair or poor health 0.829 0.982
Percent access to exercise 0.328 1.008
Percent uninsured 0.642 0.986
Percent frequent physical distress 0.522 0.852
Percent frequent mental distress 0.098 1.353
Percent lack of sleep 0.238 0.939
Percent physically inactive 0.069 1.083
[County Quartile Mental Health Providers Per Capita: base = lowest]
2nd Quartile 0.309 0.749
3rd Quartile 0.216 0.656
4th Quartile 0.027 0.421
Percent excessive drinking 0.458 0.952
Percent alcohol driving deaths 0.169 1.015
Violent crime rate 0.179 0.999
Percent child poverty 0.739 0.990
Legalized Marijuana State Law 0.900 1.043
Constant 0.960 1.155
Number of observations 590
Number of groups (counties with observations) 392
Log Pseudolikelihood − 292.352
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Table 5 Generalized Linear Multilevel Multinomial Logit Estimation for “Not a Real Medical Illness” Measure of Prescription Drug
Abuse Stigma (Versus Base of Neither Agree nor Disagree)
Strongly Agree/Agree Strongly Disagree/Disagree
Sig. Exp (B) Sig. Exp (B)
Respondent Variables:
Own Prescription Drug Abuse 0.03 4.477 0.982 1.014
Friend/family Prescription Drug Abuse 0.381 1.443 0.171 1.635
Male 0.819 0.913 0.020 0.448
White 0.978 1.013 0.339 1.593
ID: Prescription Drug Abuse 0.868 0.927 0.000 6.635
[Age base = 35–54]
Age 18–34 0.872 1.075 0.090 0.548
Age 55+ 0.761 1.175 0.081 2.068
[Respondent Income: base = $50–75)]
$25 K or less 0.563 1.426 0.336 1.711
$25-50 K 0.786 0.842 0.281 1.812
$75-100 K 0.351 1.692 0.673 1.249
$100 K+ 0.359 1.752 0.240 1.830
[Respondent Education: base = HS or less]
Some college 0.340 1.678 0.009 3.341
College degree 0.694 1.252 0.177 1.792
More than College 0.032 3.615 0.255 1.879
[Sufferer in Vignette: base = Michael]
Michelle 0.692 1.158 0.482 0.777
Regional Level Variables:
Northeast 0.006 0.124 0.215 0.408
Midwest 0.47 0.620 0.738 0.824
West 0.553 0.623 0.605 0.674
County Level Variables:
Rural 0.693 1.362 0.194 2.215
Unemployment 0.003 0.681 0.221 0.874
Association Rate 0.102 0.427 0.190 0.526
Percent fair or poor health 0.179 1.201 0.832 0.974
Percent access to exercise 0.466 1.013 0.079 1.027
Percent uninsured 0.424 0.951 0.485 1.038
Percent frequent physical distress 0.046 0.427 0.195 0.595
Percent frequent mental distress 0.194 1.576 0.145 1.612
Percent lack of sleep 0.333 1.099 0.917 0.991
Percent physically inactive 0.496 1.053 0.086 1.124
[County Quartile Mental Health Providers Per Capita: base = lowest]
2nd Quartile 0.003 5.122 0.278 0.595
3rd Quartile 0.005 7.599 0.111 2.932
4th Quartile 0.001 11.281 0.428 1.610
Percent excessive drinking 0.45 1.081 0.619 1.052
Percent alcohol driving deaths 0.969 0.999 0.850 0.997
Violent crime rate 0.102 1.002 0.817 1.000
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As shown in Table 5, we find that respondents who
self-identify as having or having had “a prescription drug
abuse issue” are about 4.5 times more likely to exhibit
stigma, when stigma is measured by the question “X’s
problem is not a real medical illness”. This might seem
counterintuitive but could be either a potential indicator
that education of people with PDA issues is incomplete,
they do not see PDA through a medical perspective, or
that they feel ashamed in not being able to deal with the
condition. We also find that correctly identifying the
condition as PDA in the vignette is associated with
much less stigma (6.6 times more likely to disagree). Be-
ing male is associated with slightly more stigma, in that
they are less likely to disagree with the statement. With
regard to education, relative to respondents with a high
school education or less, respondents with some college
were 3.3 times more likely to disagree (exhibit less
stigma) while those with high levels of education (more
than a bachelor’s) were 3.6 times more likely to agree
(exhibit more stigma). In terms of the regional and
county-level variables, respondents from the Northeast
region (as defined by US Census) were much less likely
to agree, relative to those from the Southeast (the base
region). Similarly, respondents from counties with higher
levels of unemployment and higher percentages of fre-
quent physical distress exhibited less stigma by being
less likely to agree. Finally, respondents living in counties
with higher ratios of mental health providers exhibited
very high levels of stigma relative to those from the low-
est quartile. Specifically, those in the 2nd quartile were 5
times more likely, those in the and 3rd quartile were 7.5
times more likely, while those in the 4th (highest) were
more than 11 times more likely to agree or strongly
agree that the condition was not a real medical illness.
The strength and consistency of this last result is intri-
guing and may indicate a need as well as a pathway for
educating the public about PDA. This result in combin-
ation with the fact that correct identification in counties
with higher ratios of mental health providers was also
less likely (although only significantly so in the 4th quar-
tile), might suggest targeting prevention outreach and
education about PDA within these counties and for
these outreach efforts to potentially leverage the pres-
ence of mental health providers.
Discussion
Our findings indicate there may be some additional
pathways to reducing PDA that could supplement
current efforts. Blanco, et al. [8] has suggested that rec-
ognizing PDA in the earlier stages of development is im-
portant in reversing the condition. Our work can be
used to help identify the PDA risk in the population,
thereby improving the effectiveness of prevention educa-
tion. While our findings indicate that the level of PDA
symptom recognition in the public is relatively good,
there is room for improvement. Results suggest that ef-
forts to target limited educational resources available to
teach people about this disease might focus on males
under the age of 55 given that this group had more diffi-
culty correctly identifying the condition than females
and those over 55. In our stigma model, correct identifi-
cation of the problem is strongly associated with lower
stigma felt towards those who might be experiencing
PDA. As noted by Goodyear et al. [7], reducing stigma
can help to reduce substance misuse. Thus, primary pre-
vention efforts through education might put the most
emphasis on helping the general public correctly identify
PDA symptoms, rather than in attempting to reduce
PDA stigma directly. While a primary focus on treating
individuals and fighting availability of addictive prescrip-
tion drugs such as opioids seems appropriate, an add-
itional effort in public education towards recognizing
PDA symptoms in others might assist individuals in
avoiding adverse use and, when needed, select to pursue
treatment due to potentially encouraging a higher pro-
portion of users obtaining treatment services at an early
stage in the progression of the disease. Similarly results
show that the southeast part of the US might warrant
more intensive efforts than other parts of the country.
It should be noted, however, that this study is based
on data generated through one survey conducted over a
relatively short period of time. We can therefore say
Table 5 Generalized Linear Multilevel Multinomial Logit Estimation for “Not a Real Medical Illness” Measure of Prescription Drug
Abuse Stigma (Versus Base of Neither Agree nor Disagree) (Continued)
Strongly Agree/Agree Strongly Disagree/Disagree
Sig. Exp (B) Sig. Exp (B)
Percent child poverty 0.180 1.084 0.283 1.057
Legalized Marijuana State Law 0.999 1.001 0.775 0.861
Constant 0.423 0.015 0.346 0.009
Number of observations 555
Number of groups (counties with observations) 374
Log Pseudolikelihood − 356.575
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nothing of the direction or speed of trends in knowledge
and stigma regarding these conditions. Furthermore, our
sample, while sufficient to make statements about na-
tional conditions, is insufficient to provide estimates at
the regional, state, or municipal level. It is quite likely
that regional variations within states are present, and we
may be missing important controls that would be evi-
dent if more data points were available. We also note
that our vignette was inclusive of only one aspect of
PDA and used single measure variables, suggesting that
subsequent research could both include broader indices
and examine substance specific stigma and recognition.
That said, one potential avenue suggested by our re-
sults for accomplishing better PDA education might be
to enlist mental health service providers in delivery of
general public education programs such as Mental
Health First Aid. Mental health service providers have
all the right knowledge sets to be effective in communi-
cating with the public to help broaden the general
awareness of PDA and the associated conditions, yet the
level of service provision available in the respondent’s
county is not associated with better recognition of PDA
or lower levels of stigma. Engaging these mental health
service providers to help educate the public in these
areas could help increase recognition and reduce stigma
while adding to the credibility of such campaigns and
could result in early interventions and increased rates of
successful treatments. The efficacy of different types of
targeted educational interventions should be
investigated.
Conclusions
Prescription drug abuse is likely to continue fueling the
opioid crisis. The objectives of this study were to in-
crease our understanding and knowledge about PDA
and stigma among the general public in the United
States with the hope of reducing the degree to which
PDA contributes to the crisis. To achieve these objec-
tives, we administered a randomized nation-wide survey
of the general population in the United States. Our find-
ings revealed the following. First, those who self-
identified having PDA issues were less likely to correctly
identify the condition, and more likely to demonstrate
Table 6 Multinomial Logit Estimation for “Not a Real Medical
Illness” Stigma Response to Prescription Drug Abuse (“Don’t
Know” Versus Base of “Neither Agree nor Disagree”)
Respondent Variables Sig. Exp (B)
Own Prescription Drug Abuse 0.158 0.007
Friend/family Prescription Drug Abuse 0.134 8.047
Male 0.462 0.533
White 0.558 1.952
ID: Prescription Drug Abuse 0.003 0.019
[Age base = 35–54]
Age 18–34 0.003 0.005
Age 55+ 0.851 0.797
[Respondent Income: base = $50–75)]
$25 K or less 0.518 2.262
$25-50 K 0.252 3.637
$75-100 K 0.044 0.004
$100 K+ 0.074 0.023
[Respondent Education: base = HS or less]
Some college 0.404 0.302
College degree 0.613 0.512
More than College 0.041 0.008
[Sufferer in Vignette: base = Michael]
Michelle 0.397 2.344
Regional Level Variables
Northeast 0.88 0.787
Midwest 0.007 322.140
West 0.004 3911.298
County Level Variables Sig. Exp(B)
Rural 0.705 1.986
Unemployment 0.047 0.500
Association Rate 0.217 0.181
Percent fair or poor health 0.088 1.830
Percent access to exercise 0.087 1.093
Percent uninsured 0.245 1.174
Percent frequent physical distress 0.022 0.044
Percent frequent mental distress 0.078 4.675
Percent lack of sleep 0.241 1.207
Percent physically inactive 0.004 1.979
[County Quartile Mental Health Providers Per Capita: base = lowest]
2nd Quartile 0.023 0.023
3rd Quartile 0.471 3.011
4th Quartile 0.064 0.029
Percent excessive drinking 0.711 0.906
Percent alcohol driving deaths 0.216 0.933
Violent crime rate 0.549 0.998
Percent child poverty 0.409 1.136
Table 6 Multinomial Logit Estimation for “Not a Real Medical
Illness” Stigma Response to Prescription Drug Abuse (“Don’t
Know” Versus Base of “Neither Agree nor Disagree”) (Continued)
Respondent Variables Sig. Exp (B)
Legalized Marijuana State Law 0.198 7.776
Constant 0.126 5.37e-08
Number of observations 127
Cox & Snell R-squared 0.484
Nagelkerke R-squared 0.700
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stigma. In addition, males are much less likely to identify
PDA than females. Younger people were also less likely
to correctly identify PDA. In general, males and younger
people were also more likely to exhibit stigma. These
findings can be used to improve educational efforts in
the prevention arena. Given that presence of mental
health providers seemed to present an inverse relation-
ship to desired conditions, enlisting these professionals
in education campaigns might be a cost-effective mech-
anism for progress in combating this public health men-
ace. As with any intervention, increased engagement
with mental health providers should be evaluated for
efficacy.
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